InfuSystem Holdings INFU 深 沪
等待开盘 12-20 09:30:00 美东时间
9.20
-0.320
-3.36%
华盛通- 最 高9.53
- 今 开9.46
- 成交量 23.29万股
- 最 低 8.895
- 昨 收 9.52
- 总市值 1.87亿
- 52周最高 11.04
- 市盈率 静 85.19
- 换手率 0.00%
- 52周最低 4.61
- 委 比 -2.44%
- 总股本 2033.62万
- 历史最高 23.26
- 量 比 2.28
- 振 幅 6.67%
- 历史最低 0.75
- 每 手 1
- 风险率 1.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InfuSystem Pain Management Infusion Pumps To Receive Separate Medicare Payment Under NOPAIN Act Starting January 1, 2026
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026 Rochester Hills, Michigan, December 10, 2025 - InfuSystem Holdings,
12-11 06:36
InfuSystem Holdings Announces Regulation FD Disclosure
The latest update is out from InfuSystem Holdings ( ($INFU) ). InfuSystem Holdi...
11-14 06:20
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Roth Capital Reiterates Buy on InfuSystems Holdings, Raises Price Target to $14
Roth Capital analyst Kyle Bauser reiterates InfuSystems Holdings (AMEX:INFU) with a Buy and raises the price target from $13 to $14.
11-06 01:55
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
InfuSystem Holdings Reports Strong 2024 Revenue Growth
An announcement from InfuSystem Holdings ( ($INFU) ) is now available. InfuSyst...
10-07 05:51
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Lake Street Assumes InfuSystems Holdings at Buy, Announces Price Target of $15
Lake Street analyst Benjamin Haynor assumes InfuSystems Holdings (AMEX:INFU) with a Buy rating and announces Price Target of $15.
09-22 22:02
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initi...
08-30 05:00
InfuSystem Updates Its Annual Guidance For The Full Year 2025 With Net Revenue Growth Estimated Of 6%-8%, Versus Prior Range Of 8%-10%
Full Year 2025 GuidanceInfuSystem is updating its annual guidance for the full year 2025 with net revenue growth estimated to be in the 6% to 8% range. The prior net revenue growth range was 8% to 10%. We are also
08-05 18:33
